Royalty Pharma plc RPRX

$ 26.41 0.71%

Quarterly report 2024-Q3
added 11-06-2024

Royalty Pharma plc Balance Sheet 2011-2024 | RPRX

Annual Balance Sheet Royalty Pharma plc

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	5.41 B	5.56 B	4.81 B	5.95 B	4.6 B	-	-	-	-	-	-	-
Long Term Debt	6.14 B	6.12 B	7.1 B	5.82 B	5.96 B	6.24 B	-	-	-	-	-	-	-
Long Term Debt Current	-	998 M	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	5.98 B	6.24 B	-	-	-	-	-	-	-
Total Current Liabilities	161 M	1.17 B	171 M	308 M	-	-	-	-	-	-	-	-	-
Total Liabilities	6.3 B	7.29 B	7.27 B	6.12 B	6.31 B	6.82 B	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	2.52 B	1.96 B	2.26 B	1.92 B	2.83 B	1.22 B	-	-	-	-	-	-	-
Total Assets	16.4 B	16.8 B	17.5 B	16 B	12.4 B	11.4 B	-	-	-	-	-	-	-
Cash and Cash Equivalents	477 M	1.71 B	1.54 B	1.01 B	246 M	1.92 B	-	-	-	-	-	-	-
Book Value	10.1 B	9.53 B	10.2 B	9.9 B	6.14 B	4.55 B	-	-	-	-	-	-	-
Total Shareholders Equity	10.1 B	9.53 B	10.2 B	9.9 B	6.14 B	4.55 B	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Royalty Pharma plc

	2024-Q3	2024-Q2	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	6.61 B	7.6 B	6.13 B	6.13 B	6.12 B	6.12 B	6.11 B	-	7.1 B	7.1 B	7.09 B	5.83 B	5.82 B	5.82 B	5.82 B	5.82 B	5.82 B	5.96 B	5.96 B	5.96 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	7.78 B	7.9 B	6.27 B	7.31 B	7.25 B	7.29 B	7.26 B	-	7.24 B	7.27 B	7.35 B	6.11 B	6.08 B	6.12 B	6.12 B	6.12 B	6.12 B	6.31 B	6.31 B	6.31 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	2.76 B	2.38 B	2.13 B	2.25 B	2.22 B	1.96 B	2.5 B	-	2.22 B	2.26 B	2.32 B	2.29 B	1.92 B	1.92 B	1.92 B	1.92 B	1.92 B	2.83 B	2.83 B	2.83 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	18 B	17.7 B	15.9 B	17.1 B	17.1 B	16.8 B	17.7 B	-	17.4 B	17.5 B	17.7 B	16.5 B	15.9 B	16 B	16 B	16 B	16 B	12.4 B	12.4 B	12.4 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	950 M	1.76 B	936 M	2.17 B	1.98 B	1.71 B	992 M	2.11 B	1.79 B	1.54 B	1.8 B	1.14 B	709 M	1.01 B	1.01 B	1.01 B	1.01 B	246 M	246 M	284 M	-	1.92 B	-	-	-	1.38 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	10.3 B	9.75 B	9.59 B	9.81 B	9.82 B	9.53 B	10.4 B	-	10.1 B	10.2 B	10.4 B	10.4 B	9.84 B	9.9 B	9.9 B	9.9 B	9.9 B	6.14 B	6.14 B	6.14 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	10.3 B	9.75 B	9.59 B	9.81 B	9.82 B	9.53 B	10.4 B	10.4 B	10.1 B	10.2 B	10.4 B	10.4 B	9.84 B	9.9 B	9.9 B	9.9 B	9.9 B	6.14 B	6.14 B	6.14 B	4.71 B	4.55 B	-	-	-	4.46 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency